Tristrata lawsuit
This article was originally published in The Rose Sheet
Executive Summary
Valeant Pharmaceutical's motion seeking to overturn a jury verdict finding the company infringed two patents held by Tristrata Corporation and requesting a new trial is rejected by Wilmington, Del. federal court, according to parent company NeoStrata. Court also issues a permanent injunction prohibiting Valeant from the "manufacture, sale and marketing of products covered by the infringed patents." In November, the court ruled that Valeant willfully infringed the two patents, which cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances" (1"The Rose Sheet" Dec. 1, 2003, In Brief). Patent infringement suits are still pending against other firms including Mary Kay cosmetics and BeautiControl...
You may also be interested in...
TriStrata/Mary Kay suit
Wilmington, Del. federal court denied Mary Kay's post-trial motions to set aside jury verdict in alpha hydroxy acid patent infringement case, and entered final judgment, with interest, in TriStrata's favor, NeoStrata division reports April 5. Interest on back royalties will bring total amount of the judgment to about $41.4 mil., firm notes. Mary Kay had sought to set aside a 2005 jury verdict, which found the company infringed three TriStrata patents and required direct-seller to pay $26.4 mil. TriStrata won similar AHA patent infringement cases against Valeant Pharmaceuticals, which also failed to overturn a jury verdict (1"The Rose Sheet" March 10, 2004, In Brief)...
NeoStrata patent suit
Wilmington, Del. federal court rules that Valeant Pharmaceticals willfully infringed two patents held by TriStrata Technology, a subsidiary of NeoStrata, firm announces Nov. 25. Patents cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances." Jury verdict permits treble damages, TriStrata notes. Firm also filed a motion for permanent injunction Nov. 25 to prohibit the sale of infringing products, which include Valeant's Glyquin lines. TriStrata still has a lawsuit pending against Valeant related to another product, and also has filed suit against Mary Kay and BeautiControl. Chanel, Clarins and L'Oréal are among other companies that have been the targets of TriStrata patent infringement suits (1"The Rose Sheet" Aug. 30, 1999, p. 6)...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.